HEPA
Price
$0.47
Change
-$0.01 (-2.08%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
516.56K
UBX
Price
$0.91
Change
-$0.08 (-8.08%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
16.56M
Ad is loading...

HEPA vs UBX

Header iconHEPA vs UBX Comparison
Open Charts HEPA vs UBXBanner chart's image
Hepion Pharmaceuticals
Price$0.47
Change-$0.01 (-2.08%)
Volume$445
Capitalization516.56K
Unity Biotechnology
Price$0.91
Change-$0.08 (-8.08%)
Volume$200
Capitalization16.56M
HEPA vs UBX Comparison Chart
Loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HEPA vs. UBX commentary
Apr 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HEPA is a Hold and UBX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 07, 2025
Stock price -- (HEPA: $0.48 vs. UBX: $0.99)
Brand notoriety: HEPA and UBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HEPA: 95% vs. UBX: 67%
Market capitalization -- HEPA: $516.56K vs. UBX: $16.56M
HEPA [@Biotechnology] is valued at $516.56K. UBX’s [@Biotechnology] market capitalization is $16.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HEPA’s FA Score shows that 0 FA rating(s) are green whileUBX’s FA Score has 0 green FA rating(s).

  • HEPA’s FA Score: 0 green, 5 red.
  • UBX’s FA Score: 0 green, 5 red.
According to our system of comparison, HEPA is a better buy in the long-term than UBX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HEPA’s TA Score shows that 4 TA indicator(s) are bullish while UBX’s TA Score has 4 bullish TA indicator(s).

  • HEPA’s TA Score: 4 bullish, 2 bearish.
  • UBX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, HEPA is a better buy in the short-term than UBX.

Price Growth

HEPA (@Biotechnology) experienced а -20.69% price change this week, while UBX (@Biotechnology) price change was -16.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.75%. For the same industry, the average monthly price growth was -16.58%, and the average quarterly price growth was -18.37%.

Reported Earning Dates

HEPA is expected to report earnings on Aug 30, 2023.

UBX is expected to report earnings on May 09, 2023.

Industries' Descriptions

@Biotechnology (-10.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
UBX($16.6M) has a higher market cap than HEPA($517K). UBX YTD gains are higher at: 1.393 vs. HEPA (-97.942). UBX has more cash in the bank: 23.2M vs. HEPA (1.5M). HEPA has less debt than UBX: HEPA (2.22M) vs UBX (23.5M).
HEPAUBXHEPA / UBX
Capitalization517K16.6M3%
EBITDAN/A-25.12M-
Gain YTD-97.9421.393-7,032%
P/E RatioN/AN/A-
RevenueN/A0-
Total Cash1.5M23.2M6%
Total Debt2.22M23.5M9%
FUNDAMENTALS RATINGS
HEPA vs UBX: Fundamental Ratings
HEPA
UBX
OUTLOOK RATING
1..100
7852
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9965
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HEPA's Valuation (36) in the null industry is in the same range as UBX (57) in the Biotechnology industry. This means that HEPA’s stock grew similarly to UBX’s over the last 12 months.

HEPA's Profit vs Risk Rating (100) in the null industry is in the same range as UBX (100) in the Biotechnology industry. This means that HEPA’s stock grew similarly to UBX’s over the last 12 months.

UBX's SMR Rating (99) in the Biotechnology industry is in the same range as HEPA (100) in the null industry. This means that UBX’s stock grew similarly to HEPA’s over the last 12 months.

UBX's Price Growth Rating (65) in the Biotechnology industry is somewhat better than the same rating for HEPA (99) in the null industry. This means that UBX’s stock grew somewhat faster than HEPA’s over the last 12 months.

UBX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as HEPA (100) in the null industry. This means that UBX’s stock grew similarly to HEPA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HEPAUBX
RSI
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
76%
Stochastic
ODDS (%)
N/A
Bullish Trend 6 days ago
75%
Momentum
ODDS (%)
N/A
Bearish Trend 6 days ago
84%
MACD
ODDS (%)
Bullish Trend 6 days ago
80%
Bearish Trend 6 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
87%
Advances
ODDS (%)
Bullish Trend 18 days ago
77%
Bullish Trend 25 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 6 days ago
75%
Aroon
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 6 days ago
85%
View a ticker or compare two or three
Ad is loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X83102.830000617.109400
+0.75%
Bitcoin cryptocurrency
SPY536.70-27.82
-4.93%
SPDR® S&P 500® ETF Trust
TSLA267.28-15.48
-5.47%
Tesla
GME21.10-1.59
-7.01%
GameStop Corp
AAPL203.19-20.70
-9.25%
Apple

HEPA and

Correlation & Price change

A.I.dvisor indicates that over the last year, HEPA has been loosely correlated with AVIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HEPA jumps, then AVIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HEPA
1D Price
Change %
HEPA100%
+1.21%
AVIR - HEPA
45%
Loosely correlated
+0.69%
KRYS - HEPA
33%
Poorly correlated
-1.59%
LSTA - HEPA
27%
Poorly correlated
+1.45%
UBX - HEPA
23%
Poorly correlated
-6.60%
ZYME - HEPA
23%
Poorly correlated
-1.43%
More

UBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, UBX has been loosely correlated with HOFBF. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if UBX jumps, then HOFBF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UBX
1D Price
Change %
UBX100%
-6.60%
HOFBF - UBX
34%
Loosely correlated
N/A
ASMB - UBX
33%
Poorly correlated
-1.69%
JSPR - UBX
32%
Poorly correlated
-5.20%
CVAC - UBX
30%
Poorly correlated
-0.70%
SPRC - UBX
30%
Poorly correlated
-1.18%
More